1. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A,
Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug
use disorders in Iran: prevalence, correlates, comorbidity
and service utilization results from the Iranian Mental Health
Survey. Addiction. 2016;111(10):1836-47. doi: 10.1111/
add.13453.
2. Rostami M, Karamouzian M, Khosravi A, Rezaeian S. Gender
and geographical inequalities in fatal drug overdose in Iran: a
province-level study in 2006 and 2011. Spat Spatiotemporal
Epidemiol. 2018;25:19-24. doi: 10.1016/j.sste.2018.01.001.
3. Moazen B, Shokoohi M, Noori A, Rahimzadeh S, Saeedi
Moghaddam S, Rezaei F, et al. Burden of drug and alcohol
use disorders in Iran: findings from the Global Burden of
Disease Study 2010. Arch Iran Med. 2015;18(8):480-5.
4. Ghiabi M. Maintaining disorder: the micropolitics of drugs
policy in Iran. Third World Q. 2018;39(2):277-97. doi:
10.1080/01436597.2017.1350818.
5. Nikpour G. Drugs and Drug Policy in the Islamic Republic of
Iran. Middle East Brief. 2018;(119):1-8.
6. Saberi Zafarghandi MB, Jadidi M, Khalili N. Iran’s activities on
prevention, treatment and harm reduction of drug abuse. Int
J High Risk Behav Addict. 2015;4(4):e22863. doi: 10.5812/
ijhrba.22863.
7. Ansari-Moghaddam A, Rakhshani F, Shahraki-Sanavi F,
Mohammadi M, Miri-Bonjar M, Bakhshani NM. Prevalence
and patterns of tobacco, alcohol, and drug use among Iranian
adolescents: a meta-analysis of 58 studies. Child Youth Serv
Rev. 2016;60:68-79. doi: 10.1016/j.childyouth.2015.11.018.
8. Vallersnes OM, Jacobsen D, Ekeberg Ø, Brekke M.
Mortality, morbidity and follow-up after acute poisoning
by substances of abuse: a prospective observational cohort
study. Scand J Public Health. 2019;47(4):452-61. doi:
10.1177/1403494818779955.
9. Haukka J, Kriikku P, Mariottini C, Partonen T, Ojanperä
I. Non-medical use of psychoactive prescription drugs is
associated with fatal poisoning. Addiction. 2018;113(3):464-
72. doi: 10.1111/add.14014.
10. Naghavi M, Shahraz S, Ghajarieh Sepanlou S, Dicker D,
Naghavi P, Pourmalek F, et al. Health transition in Iran toward
chronic diseases based on results of Global Burden of Disease
2010. Arch Iran Med. 2014;17(5):321-35.
11. Wyatt TM, Dejong W, Dixon E. Population-level
administration of AlcoholEdu for college: an ARIMA timeseries analysis. J Health Commun. 2013;18(8):898-912. doi:
10.1080/10810730.2011.626501.
12. Babakhanian M, Zarghami M, Alipour A, Khosravi A,
Hashemi-Nazari SS, Saberi M, et al. An estimation of drugrelated deaths in Iran, using the capture-recapture method
(2014-2016). Addict Health. 2020;12(2):87-97. doi:
10.22122/ahj.v12i2.266.
13. Zivetz L. The ICD-10 Classification of Mental and Behavioural
Disorders: Clinical Descriptions and Diagnostic Guidelines.
Geneva: World Health Organization; 1992.
14. Hyndman R. Forecasting Functions for Time Series and Linear
Models. R package version 6.1. Available from: https://cran.rproject.org/web/packages/forecast/index.html.
15. Rahimipoor I, Habibzadeh M, Mohaghegh Damad M,
Farajiha M, Omidi J. A comparative study of Iran legislative
policy with Portugal and Canada. Comparative Law Research
Quarterly. 2016;20(3):84-109. [Persian].
16. Dye DW, McGwin G, Atherton DS, McCleskey B, Davis GG.
Correctly identifying deaths due to drug toxicity without a
forensic autopsy. Am J Forensic Med Pathol. 2019;40(2):99-
101. doi: 10.1097/paf.0000000000000465.
17. Bastani P, Marshall BDL, Rahimi-Movaghar A, Noroozi A.
The risk environments of people who use drugs accessing
two harm reduction centers in Tehran, Iran: a qualitative
study. Int J Drug Policy. 2019;63:90-6. doi: 10.1016/j.
drugpo.2018.11.013.
18. Shahbazi F, Mirtorabi D, Ghadirzadeh MR, Hashemi-Nazari
SS. Analysis of mortality rate of illicit substance abuse and
its trend in five years in Iran, 2014-2018. Addict Health.
2018;10(4):260-8. doi: 10.22122/ahj.v10i4.602.
19. Shiels MS, Berrington de González A, Best AF, Chen Y,
Chernyavskiy P, Hartge P, et al. Premature mortality from
all causes and drug poisonings in the USA according to
socioeconomic status and rurality: an analysis of death
certificate data by county from 2000-15. Lancet Public Health.
2019;4(2):e97-e106. doi: 10.1016/s2468-2667(18)30208-1.
20. Akhgari M, Amini-Shirazi N, Sardari Iravani F. Forensic
toxicology perspectives of methadone-associated deaths
in Tehran, Iran, a 7-year overview. Basic Clin Pharmacol
Toxicol. 2018;122(4):436-41. doi: 10.1111/bcpt.12930.
21. Jones CM, Einstein EB, Compton WM. Changes in synthetic
opioid involvement in drug overdose deaths in the United
States, 2010-2016. JAMA. 2018;319(17):1819-21. doi:
10.1001/jama.2018.2844.
22. Khayyati F, Asghari Jafarabadi M, Lotfizadeh M, Karimi
A, Rahmani K. Effectiveness of a community and schoolbased intervention to control and prevent of tobacco use in
adolescents: a field randomized controlled trial. Iran J Public
Health. 2019;48(1):187-8.
23. Ladis BA, Macgowan M, Thomlison B, Fava NM, Huang H,
Trucco EM, et al. Parent-focused preventive interventions for
youth substance use and problem behaviors: a systematic
review. Res Soc Work Pract. 2019;29(4):420-42. doi:
10.1177/1049731517753686.
24. Bjerre Christensen J. Human rights and wrongs in Iran’s drug
diplomacy with Europe. Middle East J. 2017;71(3):403-32.
doi: 10.3751/71.3.14.
25. Vicknasingam B, Narayanan S, Singh D, Chawarski M.
Decriminalization of drug use. Curr Opin Psychiatry.
2018;31(4):300-5. doi: 10.1097/yco.0000000000000429.
26. Godwin J. A Public Health Approach to Drug Use in Asia:
Principles and Practices for Decriminalisation. United
Kingdom: IDPC Publications; 2016.
27. Baer D. 6 incredible things that happened when Portugal
decriminalized all drugs. Business Insider. Available from:
https://www.businessinsider.com/what-happened-whenportugal-decriminalized-all-drugs-2016-3.
28. De Giorgi R, Cassar C, Loreto D’alò G, Ciabattini M, Minozzi
S, Economou A, et al. Psychosocial interventions in stimulant
use disorders: a systematic review and qualitative synthesis of
randomized controlled trials. Riv Psichiatr. 2018;53(5):233-
55. doi: 10.1708/3000.30003.
29. Box GE, Jenkins GM, Reinsel GC, Ljung GM. Time Series
Analysis: Forecasting and Control. John Wiley & Sons; 2015.